Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers

References

• Sharma SR, Gonda X. Tarazi FI Autism spectrum disorder: classification, diagnosis and therapy. Pharmacol Ther. 2018;190:91–104.
   PubMed Web of Science ®Google Scholar
• Baio J, Wiggins L, Christensen DL, et al. Prevalence of autism spectrum disorder among children aged 8 years - Autism and developmental disabilities monitoring network, 11 sites, United States. MMWR Surveill Summ. 2018;67(6):1–23.
   PubMed Web of Science ®Google Scholar
• Baird G, Simonoff E, Pickles A, et al. (Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet. 2006;368(9531):210–215.
   PubMed Web of Science ®Google Scholar
• Elsabbagh M, Divan G, Koh YJ, et al. Global prevalence of autism and other pervasive developmental disorders. Autism Res. 2012;5(3):160–179.
   PubMed Web of Science ®Google Scholar
• Torres N, Martins D, Santos AJ, et al. How do hypothalamic nonapeptides shape youth’s sociality? A systematic review on oxytocin, vasopressin and human socio-emotional development. Neurosci Biobehav Rev. 2018;90:309–331.
   PubMed Web of Science ®Google Scholar
• Frye RE. Social skills deficits in autism spectrum disorder: potential biological origins and progress in developing therapeutic agents. CNS Drugs. 2018;32(8):713–734.
   PubMed Web of Science ®Google Scholar
• Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab. 2000;11(10):406–410.
   PubMed Web of Science ®Google Scholar
• Koshimizu TA, Nasa Y, Tanoue A, et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci U S A. 2006;103:7807–7812.
   PubMed Web of Science ®Google Scholar
• Engelmann M, Landgraf R, Wotjak CT. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neuroendocrinol. 2004;25(3–4):132–149.
   PubMed Web of Science ®Google Scholar
• Insel TR. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron. 2010;65(6):768–779.
   PubMed Web of Science ®Google Scholar
• Hammock EAD, Young LJ. Oxytocin, vasopressin and pair bonding: implications for autism. Philos Trans R Soc Lond B Biol Sci. 2006;361(1476):2187–2198.
   PubMed Web of Science ®Google Scholar
• Kim S-J, Young LJ, Gonen D, et al. disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Mol Psychiatry. 2002;7:503–507.
   PubMed Web of Science ®Google Scholar
• Wassink TH, Piven J, Vieland VJ, et al. Examination of AVPR1a as an autism susceptibility gene. Mol Psychiatry. 2004;9(10):968–972.
   PubMed Web of Science ®Google Scholar
• Yirmiya N, Rosenberg C, Levi S, et al. Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Mol Psychiatry. 2006;11(5):488–494.
   PubMed Web of Science ®Google Scholar
• Yang SY, Cho S-C, Yoo HJ, et al. Association study between single nucleotide polymorphisms in promoter region of AVPR1A and Korean autism spectrum disorders. Neurosci Lett. 2010;479:197–200.
   PubMed Web of Science ®Google Scholar
• Yang SY, Kim SA, Hur GM, et al. Replicative genetic association study between functional polymorphisms in AVPR1A and social behavior scales of autism spectrum disorder in the Korean population. Mol Autism. 2017;8:44.
   PubMed Web of Science ®Google Scholar
• Tansey KE, Hill MJ, Cochrane LE, et al. Functionality of promoter microsatellites of arginine vasopressin receptor 1A (AVPR1A): implications for autism. Mol Autism. 2011;2(1):3.
   PubMedGoogle Scholar
• Parker KJ, Oztan O, Libove RA, et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Sci Transl Med. 2019;11(491):eaau7356.
   PubMed Web of Science ®Google Scholar
• Uzefovsky F, Shalev I, Israel S, et al. Vasopressin selectively impairs emotion recognition in men. Psychoneuroendocrinology. 2012;37(4):576–580.
   PubMed Web of Science ®Google Scholar
• Thompson R, Gupta S, Miller K, et al. The effects of vasopressin on human facial responses related to social communication. Psychoneuroendocrinology. 2004;29(1):35–48.
   PubMed Web of Science ®Google Scholar
• Umbricht D, Del Valle Rubido M, Hollander E, et al. A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology. 2017;42:1914–1923.
   PubMed Web of Science ®Google Scholar
• Schnider P, Bissantz C, Bruns A, et al. Discovery of balovaptan, a vasopressin 1a receptor antagonist for the treatment of autism spectrum disorder. J Med Chem. 2020;63(4):1511–1525.
   PubMed Web of Science ®Google Scholar
• Bolognani F, Del Valle Rubido M, Squassante L, et al. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. 2019;11(491):eaat7838.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for industry: food-effect bioavailability and bioequivalence studies. 2002. cited 2020 Nov 24. Available from: https://www.fda.gov/files/drugs/published/Food-Effect-Bioavailability-and-Fed-Bioequivalence-Studies.pdf
   Google Scholar
• DHHS/FDA/CDER. Guidance for Industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2017. cited 2020 Nov 24. Available from: https://www.fda.gov/media/70963/download
   Google Scholar
• Olivares-Morales A, Kamiyama Y, Darwich AS, et al. Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. Eur J Pharm Sci. 2015;67:32–44.
   PubMed Web of Science ®Google Scholar
• Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977;5:625–653.
   PubMedGoogle Scholar
• Matsui D. Current issues in pediatric medication adherence. Paediatr Drugs. 2007;9(5):283–288.
   PubMedGoogle Scholar
• Chacko A, Newcorn JH, Feirsen N, et al. Improving medication adherence in chronic pediatric health conditions: a focus on ADHD in youth. Curr Pharm Des. 2010;16(22):2416–2423.
   PubMed Web of Science ®Google Scholar
• Winnick S, Lucas DO, Hartman AL, et al. How do you improve compliance? Pediatrics. 2005;115(6):e718–e724.
   PubMed Web of Science ®Google Scholar
• Logan SL, Carpenter L, Leslie SR, et al. Rates and predictors of adherence to psychotropic medications in children with autism spectrum disorders. J Autism Dev Disord. 2014;44(11):2931–2948.
   PubMed Web of Science ®Google Scholar
• El-Rachidi S, LaRochelle JM, Morgan JA. Pharmacists and pediatric medication adherence: bridging the gap. Hosp Pharm. 2017;52(2):124–131.
   PubMedGoogle Scholar
• Santer M, Ring N, Yardley L, et al. Treatment non-adherence in pediatric long-term medical conditions: systematic review and synthesis of qualitative studies of caregivers’ views. BMC Pediatr. 2014;14:63.
   PubMed Web of Science ®Google Scholar
• Derks M, Wandel C, Jordan P, et al. No clinically relevant effect of balovaptan on electrocardiography, heart rate, or blood pressure in healthy volunteers. INSAR. 2020 Abstract 416.003
   Google Scholar